Found: 17
Select item for more details and to access through your institution.
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer.
- Published in:
- EMBO Molecular Medicine, 2019, v. 11, n. 12, p. N.PAG, doi. 10.15252/emmm.201910581
- By:
- Publication type:
- Article
Characterization and validation of an alternative reference bacterium Korean Pharmacopoeia Staphylococcus aureus strain.
- Published in:
- Journal of Microbiology, 2022, v. 60, n. 2, p. 187, doi. 10.1007/s12275-022-1335-5
- By:
- Publication type:
- Article
Neutralizing Antibody Responses and Evolution of the Viral Envelope in the Course of HIV-1 Korean Clade B Infection
- Published in:
- Osong Public Health & Research Perspectives, 2011, v. 2, n. 3, p. 151, doi. 10.1016/j.phrp.2011.11.038
- By:
- Publication type:
- Article
BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359241280689
- By:
- Publication type:
- Article
DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor–resistant lung cancer therapy.
- Published in:
- Experimental & Molecular Medicine EMM, 2022, v. 54, n. 8, p. 1236, doi. 10.1038/s12276-022-00836-7
- By:
- Publication type:
- Article
Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221079125
- By:
- Publication type:
- Article
ARTIST: An activated method in internal coordinate space for sampling protein energy landscapes.
- Published in:
- Proteins, 2006, v. 63, n. 4, p. 967, doi. 10.1002/prot.20938
- By:
- Publication type:
- Article
Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-019-56356-4
- By:
- Publication type:
- Article
Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus.
- Published in:
- PLoS ONE, 2020, v. 15, n. 5, p. 1, doi. 10.1371/journal.pone.0232757
- By:
- Publication type:
- Article
Novel allosteric glutaminase inhibitors with macrocyclic structure activity relationship analysis (part 2).
- Published in:
- Bulletin of the Korean Chemical Society, 2024, v. 45, n. 7, p. 639, doi. 10.1002/bkcs.12883
- By:
- Publication type:
- Article
Correction to: Genetic diversity and evolutionary history of Korean isolates of severe fever with thrombocytopenia syndrome virus from 2013–2016.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Genetic diversity and evolutionary history of Korean isolates of severe fever with thrombocytopenia syndrome virus from 2013–2016.
- Published in:
- Archives of Virology, 2020, v. 165, n. 11, p. 2599, doi. 10.1007/s00705-020-04733-0
- By:
- Publication type:
- Article
The clinical and virological features of the first imported case causing MERS-CoV outbreak in South Korea, 2015.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck.
- Published in:
- 2020
- By:
- Publication type:
- journal article
SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models.
- Published in:
- Clinical & Translational Immunology, 2022, v. 11, n. 1, p. 1, doi. 10.1002/cti2.1364
- By:
- Publication type:
- Article
Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.821391
- By:
- Publication type:
- Article